Medicare has been banned from covering weight loss drugs since 2003. CMS launched BALANCE in December 2025, a voluntary model offering $50-per-month Ozempic and Wegovy access for 10% of Medicare enrollees starting July 2026.
The workaround: call it treatment for chronic disease with specific comorbidities, not weight loss coverage. Manufacturer applications closed January 8, 2026, with negotiations continuing through February 28. Meanwhile, California, Pennsylvania, and Michigan cut adult Medicaid GLP-1 coverage on January 1, 2026 due to budget pressures, while CMS pursues federal expansion.
Novo Nordisk launched the first oral GLP-1 weight loss pill on January 5, 2026, potentially changing cost dynamics that underpin CBO projections of $35 billion through 2034. These state cuts reflect mounting fiscal anxiety. The model's success depends on whether manufacturers accept $245 pricing to access 40 million beneficiaries and whether state and federal programs can sustain these costs.
24 events
Latest: December 31st, 2031
Showing 8 of 24
JK to step
Tap a bar to jump to that date
Jump to
December 2031
BALANCE Demonstration Ends
LatestProgram Milestone
Initial demonstration period concludes; CMS evaluates results for permanent coverage decision.
January 2027
Medicare BALANCE Full Launch
Implementation
Part D plans can offer GLP-1 coverage through BALANCE model nationwide.
July 2026
Medicare Bridge Demo Begins
Implementation
Short-term demonstration gives Medicare Part D beneficiaries $50/month GLP-1 access before full BALANCE launch.
May 2026
Medicaid BALANCE Launch
Implementation
State Medicaid programs can begin voluntary participation in GLP-1 coverage model.
February 2026
Manufacturer Negotiation Deadline
Deadline
CMS must complete negotiations and execute Participation Agreements with manufacturers who submitted applications by January 8. Manufacturers accepting terms become official BALANCE participants.
January 2026
Manufacturer Applications Due
Deadline
Eli Lilly and Novo Nordisk must submit BALANCE participation applications to CMS.
BALANCE Applications and Notices of Intent Due
Deadline
Manufacturer applications, state Medicaid agency notices of intent, and Part D plan notices of intent submitted to CMS. Participation agreements to be negotiated through February 28, 2026.
Novo Nordisk Launches Oral Wegovy Nationwide
Market Development
First oral GLP-1 weight loss pill becomes broadly available at US pharmacies including CVS and Costco. Starter dose priced at $149/month for self-pay patients. Pill demonstrated 16.6% mean weight loss in OASIS 4 trial, with one in three participants achieving 20%+ weight loss.
Three States Cut Medicaid GLP-1 Weight Loss Coverage
State Policy
California, Pennsylvania, and Michigan eliminate adult Medicaid coverage for GLP-1s prescribed solely for weight loss, citing budget constraints. California removes Wegovy, Zepbound, and Saxenda from formulary for weight loss; coverage continues for diabetes indications. Children under 21 retain coverage under federal EPSDT protections.
December 2025
Obesity Medicine Association Endorses BALANCE Model
Professional Response
OMA releases position statement commending CMS and pharmaceutical partners for BALANCE model, calling it recognition of obesity as chronic disease requiring comprehensive medical treatment. Organization urges removal of preauthorization barriers and uniform prescribing access for physicians, NPs, and PAs.
CMS Launches BALANCE Model
Program Launch
Voluntary demonstration program announced enabling GLP-1 access for 10% of Medicare enrollees with specific comorbidities starting mid-2026.
FDA Approves First Oral GLP-1 for Weight Loss
Regulatory
FDA approves Novo Nordisk's Wegovy pill (once-daily oral semaglutide 25 mg), first oral GLP-1 receptor agonist for chronic weight management and cardiovascular risk reduction. Approval based on OASIS 4 trial showing 16.6% mean weight loss.
November 2025
Trump Announces Manufacturer Deals
Negotiation
Administration negotiates $245 pricing with Eli Lilly and Novo Nordisk, with $50 beneficiary copays for limited Medicare access.
April 2025
Trump Announces No Traditional Coverage
Policy
Administration declares Medicare and Medicaid will not cover anti-obesity drugs through standard benefit expansion.
CMS proposes reinterpreting statutory ban, classifying obesity drugs as chronic disease treatment to enable Medicare/Medicaid coverage for 7.4M Americans.
October 2024
CBO Projects $35B Cost
Analysis
Congressional Budget Office estimates Medicare obesity drug coverage would cost $35 billion 2026-2034, with minimal health savings offsetting.
November 2023
Zepbound Approved for Weight Management
Regulatory
FDA approves tirzepatide for obesity treatment; Eli Lilly captures market share from Novo Nordisk.
August 2022
Inflation Reduction Act Enacted
Legislative
Biden signs law giving Medicare drug price negotiation power for first time, capping insulin at $35/month and out-of-pocket costs at $2,000.
May 2022
FDA Approves Mounjaro
Regulatory
Eli Lilly's tirzepatide approved for diabetes; shows superior weight loss versus semaglutide.
June 2021
Wegovy Approved for Weight Management
Regulatory
FDA approves higher-dose semaglutide specifically for chronic weight management, legitimizing GLP-1 obesity treatment.
December 2017
FDA Approves Ozempic
Regulatory
Novo Nordisk's semaglutide approved for Type 2 diabetes; off-label weight loss use follows.
June 2013
AMA Classifies Obesity as Disease
Medical
American Medical Association votes 60-40 to recognize obesity as chronic disease with "multiple pathophysiological aspects," contradicting its own committee recommendation.
December 2003
Medicare Modernization Act Signed
Legislative
President Bush signs law creating Part D prescription drug benefit while explicitly banning coverage of weight loss drugs, treating obesity as cosmetic condition.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1 of 3
2014-2015
Hepatitis C Drug Coverage Expansion (2014)
FDA approved Sovaldi, a $1,000-per-pill cure for hepatitis C. Medicare Part D spending on hepatitis C drugs exploded from $283 million in 2013 to $4.5 billion in 2014—a 16x increase overnight. Despite sticker shock, CMS expanded coverage because drugs actually cured a deadly communicable disease. State Medicaid programs faced budget crises but eventually provided access.
Then
Initial budget panic and state rationing of treatments to sickest patients first.
Now
Universal Part D plan coverage by 2015; hepatitis C drugs became standard benefit despite costs.
Why this matters now
Shows Medicare can absorb massive drug spending increases when clinical benefit is clear—but hepatitis C cured patients, while GLP-1s require indefinite use.
2 of 3
2003-2006
Medicare Part D Creation (2003-2006)
Medicare Modernization Act of 2003 created the Part D prescription drug benefit, Medicare's largest expansion since its 1965 founding. The law explicitly excluded coverage for weight loss, weight gain, cosmetic purposes, and fertility—reflecting 2003 attitudes that obesity was a lifestyle choice, not a disease. The exclusion was borrowed from Medicaid statute and embedded in Medicare's foundational prescription drug architecture.
Then
Part D launched January 2006 with weight loss ban intact; no controversy at the time.
Now
Ban remained unquestioned for 18 years until GLP-1 efficacy and AMA disease classification created pressure.
Why this matters now
The statutory exclusion wasn't ideological—it reflected medical consensus circa 2003. Changing it requires either legislation or creative reinterpretation like BALANCE.
3 of 3
1987-1990
AIDS Drug Assistance Program (1987-1990)
As HIV/AIDS epidemic overwhelmed patients with antiretroviral costs exceeding $10,000 annually, advocacy groups pushed federal government to create AIDS Drug Assistance Program (ADAP) in 1987, formalized in 1990 Ryan White CARE Act. Program provided federal funding specifically for HIV medications outside traditional insurance structures. Medicaid became largest payer for HIV treatment, covering 40%+ of people with HIV.
Then
ADAP enabled access to lifesaving antiretrovirals for uninsured and underinsured patients.
Now
Created precedent for disease-specific federal drug assistance programs; HIV drugs eventually gained broad insurance coverage.
Why this matters now
Disease-specific programs can bypass traditional coverage restrictions when public health stakes are high—but BALANCE faces questions about whether obesity justifies similar treatment.
